Macular vessel reduction as predictor for recurrence of macular oedema requiring repeat intravitreal ranibizumab injection in eyes with branch retinal vein occlusion.

CONCLUSIONS: Patients with BRVO with a large macular vessel reduction at 1 month after an initial IVR injection have fewer recurrences and thus lower frequency of IVR injections during 12 months. PMID: 30514711 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30514711?dopt=Abstract

Source: The British Journal of Ophthalmology - December 4, 2018 Category: Opthalmology Authors: Hasegawa T, Takahashi Y, Maruko I, Kogure A, Iida T Tags: Br J Ophthalmol Source Type: research